Climb Bio, Inc. (CLYM) · Aug 14, 2026 · Other events
In line — First patient dosed in Q3 2026, as previously expected
Climb Bio’s partner dosed the first IgA nephropathy patient in China, confirming the Q3 plan but adding no efficacy or safety evidence.
The milestone landed inside the existing timeline. Climb Bio had already indicated that Mabworks expected to begin dosing IgA nephropathy patients in the Phase 2 portion of the study during the third quarter of 2026. The August 13 announcement therefore confirms execution rather than delivering a timing surprise.
The filing confirms trial advancement, not clinical success. Beijing Mabworks dosed the first patient in a China Phase 2 IgA nephropathy trial conducted with Climb Bio. 〔0〕 There are no patient efficacy results, safety findings, enrollment numbers, or revised development timelines in this 8-K.
Net: an execution confirmation, not a new value inflection. Because the direction and timing were already broadly expected, the filing is best scored In line: it removes some execution uncertainty around CLYM116 but does not yet change the clinical evidence base or establish that the drug works in IgA nephropathy.
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!